financetom
Business
financetom
/
Business
/
Novanta's Q2 sales, profit beats estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Novanta's Q2 sales, profit beats estimates
Aug 5, 2025 4:28 AM

Overview

* Novanta ( NOVT ) Q2 GAAP revenue up 2% to $241 mln, beating estimates

* Adjusted EPS for Q2 at $0.76, surpassing analyst expectations

* Company updates full-year 2025 financial guidance

Outlook

* Novanta ( NOVT ) expects full-year 2025 GAAP revenue of $970 mln to $985 mln

* Company anticipates Q3 2025 GAAP revenue of $244 mln to $247 mln

* Novanta ( NOVT ) sees full-year 2025 Adjusted EBITDA of $225 mln to $230 mln

* Company expects Q3 2025 Adjusted EPS of $0.78 to $0.85; FY adjusted EPS of $3.22 to $3.36

Result Drivers

* ACQUISITIONS AND FX - Revenue growth driven by acquisitions and favorable foreign exchange rates

* BOOKINGS GROWTH - 10% increase in bookings with improvement in industrial business

* SEGMENT GROWTH - Mid-teens revenue growth in Advanced Surgery and Robotics & Automation segments

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $241 mln $238 mln

Revenue (3

Analysts

)

Q2 Beat $0.76 $0.73 (3

Adjusted Analysts

EPS )

Q2 $4.50

Consolid mln

ated Net

Income

Q2 Beat $52.20 $51.50

Adjusted mln mln (2

EBITDA Analysts

)

Q2 Beat $40.70 $39.90

Adjusted mln mln (3

Operatin Analysts

g Income )

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the electronic equipment & parts peer group is "buy"

* Wall Street's median 12-month price target for Novanta Inc ( NOVT ) is $158.50, about 21.8% above its August 4 closing price of $124.01

* The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 32 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Bayer: U.S. Supreme Court could decide in June whether it will hear glyphosate case
Bayer: U.S. Supreme Court could decide in June whether it will hear glyphosate case
May 26, 2025
FRANKFURT, May 13 (Reuters) - Bayer said on Tuesday that the U.S. Supreme Court could decide as early as next month whether it will hear the German company's request to sharply limit litigation that could run into the billions of dollars over disputed claims that its Roundup weedkiller causes cancer. There are two windows that we could hear (from the...
DexCom Adds President Role to COO Jake Leach
DexCom Adds President Role to COO Jake Leach
May 26, 2025
09:02 AM EDT, 05/13/2025 (MT Newswires) -- DexCom ( DXCM ) said Tuesday that it has added the role of president to its chief operating officer, Jake Leach. DexCom ( DXCM ) said Leach will now also oversee the company's corporate development and strategic initiatives as part of his expanded position. ...
Altimmune Secures Credit Facility of Up to $100 Million From Hercules Capital
Altimmune Secures Credit Facility of Up to $100 Million From Hercules Capital
May 26, 2025
09:03 AM EDT, 05/13/2025 (MT Newswires) -- Altimmune ( ALT ) said Tuesday it entered into an agreement with Hercules Capital ( HTGC ) for a credit facility of up to $100 million, with $15 million funded at closing. The company said additional funding will be tied to the achievement clinical and financial milestones for pemvidutide, its GLP-1 agonist. Pemvidutide...
Copyright 2023-2026 - www.financetom.com All Rights Reserved